Jump to content



Recommended Posts

So we may as well continue our trials with the Ftse, I've kept away from this and gbpusd for a long time since the brexit made them very difficult to read but never the less I need another live market to play on. 

To recap we are looking to the first hour of market open to try to identify the session high or low, from there we are using the 14 daily average of the average true range to set a target for the day. So it's a bit like the London Breakout Strategy but we are not looking identify the breakout but rather looking to identify it's base. The easiest way to keep score is to let IG do the leg work by simply placing a long call or put on demo.


LT bull, MT neutral, ST bear/neutral. ATR is currently 52 points.

So looking at the chart and rather annoyingly ftse seems to be already taking off to the upside, before the eur open even, but we'll stick to the rules that I'm making up as I go along for er ... reasons.

Currently we are looking at a session low of 7338 which is the value area low and a ATR target which coincides with R1.


Link to comment

An hour into the London session and Ftse is already at the proposed target set this morning so I may have to re-think my 'rules', any suggestions?  The reason for the 1 hour wait was that I've seen stats (somewhere, long ago, probably made up) that the session low or high is in within the first hour after open some 75% of the time. 

The base did look sound and the chart was short term very bullish well before the Eur open so perhaps should have just pulled the trigger on the off in such a situation.



Link to comment
5 minutes ago, FOXY said:

Ftse looking to break up through 7369.

Yes, Ftse trying to follow Dax which is trying to push down through the large bear candle bottom put in at 9:30 yesterday evening but Dow not bothered at the mo and currently has support at today's point of control (red dash).

It's setting up similar to yesterday which saw dax and ftse turn around and follow dow up after the US open.


Link to comment

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!

Register a new account

Sign in

Already have an account? Sign in here.

Sign In Now
  • General Statistics

    • Total Topics
    • Total Posts
    • Total Members
    • Most Online
      10/06/21 10:53

    Newest Member
    Joined 08/12/21 14:37
  • Posts

    • U.S. INDICES TECHNICAL HIGHLIGHTS: S&P 500 surges off support, new record high near Dow Jones finds significant support around the 200-day Nasdaq 100 top of channel test nearing again Dow Jones, S&P 500, Nasdaq 100 Forecast: Stocks Staring at New Highs Momentarily the S&P 500 broke the old high created in September, tagged the trend-line from October 2020, and then sprung higher. The volatility around the old high and trend-line were cues that something like this could happen. The October trend-line, which previously had the bare minimum to make up a trend-line given it had only two connecting points, has now been validated as a truly meaningful line of support. Should we see a revisit of that line in the near future it could hold a good risk/reward opportunity for fresh longs. Right now a test of the trend-line doesn’t look likely. Stocks are strong and near highs, in aggregate. The momentum has been fierce coming out of the low, which is normal, now stock momentum is likely to diminish as new highs come into focus. A new record will be recorded once the SPX breaks 4743. For now, looking for stocks to trade to new highs, it appears a Santa rally may be in the works. Until we see pervasive price action that takes out key line and levels, there appears to be no reason to be bearish at this time.     S&P 500 DAILY CHART S&P 500 Chart by TradingView The Dow Jones behaved around the 200-day moving average in very typical fashion. This is what was said last week, “We may see a solid push through the 200 initially, tag off of support below, then reversal higher.” That is exactly what happened. On Dec 1 we saw a slice through the 200-day to support beneath it followed by a recovery beginning the following day. The current leg higher is set to run with less steam, but look for the old high at 36565 to come into play. Since April the Dow may undergoing a broadening top type of sequence, but we’ll leave that on the backburners until it becomes more relevant. For now, staying the course on the upside. DOW JONES DAILY CHART Dow Jones Chart by TradingView The Nasdaq 100 was putting in a head-and-shoulders pattern around the top of a channel dating to September 2020, but that idea was quickly put to rest once the old high in September was met and held. A top-side test here will be interesting, because it will mean that the top of the channel is coming under pressure again. Can the NDX leave the gravity of the channel, or will it continue to keep the rally contained? It’s a big question, because once price escapes the top of these kind of patterns we can see an impressive acceleration unfold thereafter. NASDAQ 100 DAILY CHART Nasdaq 100 Chart by TradingView Resources for Forex Traders Whether you are a new or experienced trader, we have several resources available to help you; indicator for tracking trader sentiment, quarterly trading forecasts, analytical and educational webinars held daily, trading guides to help you improve trading performance, and one specifically for those who are new to forex. Written by Paul Robinson, Market Analyst, 8th December 2021. DailyFX
    • The deliberate deception is coming from Pfizer actually, see the math as used in this case. 'VIDEO: Covid Vaccines - Relative vs Absolute Efficacy. Did Pfizer oversell their product? Date  Fri 03 December 2021 By  InProportion2 Tags vaccine / videos ''When Pfizer launched its vaccine they told the world that it had a relative efficacy of 95%. Some months later the Lancet pointed out that it had an absolute efficacy of only 0.84%. Both values were correct, but which was more informative?''   VIDEO: Covid Vaccines - Relative vs Absolute Efficacy. Did Pfizer oversell their product? - InProportion2 (talkigy.com)  
  • Create New...